Erez Aminov is the Chairman and Chief Executive Officer of MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a clinical-stage biopharmaceutical company at the forefront of developing innovative treatments for neuropsychiatric disorders. Under his leadership, MIRA is advancing transformative therapies such as MIRA55 and Ketamir-2, aiming to address critical unmet medical needs with safe and effective solutions.

With a deep expertise in biotechnology consulting, investment, and leadership, Mr. Aminov has played a pivotal role in shaping the biopharma landscape. Prior to joining MIRA, he founded Locate Venture Corp, where he supported early-stage biotech enterprises and fostered growth through strategic partnerships. He has also served as a trusted consultant for multiple biotech firms and successfully guided two companies through IPOs on the Nasdaq, showcasing his ability to navigate complex financial and regulatory environments.

At MIRA, Mr. Aminov has been instrumental in securing funding, licensing proprietary technologies, and overseeing the submission of Investigational New Drug (IND) applications. His strategic vision continues to position MIRA for success, with pivotal preclinical studies paving the way for clinical advancements.

In addition, Mr. Aminov serves as the Chairman and Chief Executive Officer of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a biotechnology company dedicated to developing Telomir-1, an innovative therapeutic targeting telomere elongation and protection to treat age- related inflammatory and degenerative conditions.

Mr. Aminov holds a Bachelor of Arts in Accounting from Touro University in New York. His unique blend of financial acumen and forward-thinking leadership drives his mission to advance groundbreaking therapies and deliver value to stakeholders.

Itzchak Angel is an accomplished executive in the pharmaceutical industry, with over 40 years’ experience guiding medical, pharmaceutical, drug and business development in both large and emerging companies. Since 2005, he has been President and CEO of Angel Pharmaceutical Consulting & Technologies (A.P.C.T.) where he assists pharmaceutical and biotechnology companies, individuals, medical staff, hospitals, technology transfer companies, investors, university researchers and research teams in variable aspects of drug development. In this role, Dr. Angel provides strategic and operational guidance on issues related to ethical drug development to a wide range of clients, including pharmaceutical and biotechnology companies, medical professionals, hospitals, technology transfer organizations, investors, and research teams. His expertise spans a variety of therapeutic areas and pharmacological families and extends across the drug development process–from research, preclinical and clinical phases, to marketing. In addition, Dr. Angel advises on regulatory affairs, business development, and organizational planning.

Dr. Angel’s journey in the sciences began with his education at the Tel-Aviv University, where he earned his B. Sc, and M.Sc. degrees in Biology in 1979 and 1980, taking part in a special curriculum for outstanding students. He further studied at the Hamburg University, Germany, obtaining a Ph.D. in Neurochemistry in 1982. His postdoctoral research took him to the National Institute of Mental Health in Bethesda, Maryland, where he pursued his research in Neurobiology. For numerous years, he was Head of Pharmacology at Synthelabo (Sanofi-Aventis, Paris, France) where he participated in the research and development of drugs such as Xatral (alfuzosin), Ambien (zolpidem), and Mizollen (mizolastine). Some of Dr. Angel's previous executive roles include President and Chief Executive Officer of the stem-cell company Accellta (Haifa, Israel) and Vice President for Research and Development at Proteologics Ltd, Galmed Pharmaceuticals, and D-Pharm Biopharmaceuticals (Rehovot, Israel), where he was involved in research and advanced development in several areas such as stroke, epilepsy, Alzheimer’s’ Disease, Parkinson’s disease, metabolic disorders, psoriasis, and various cancers.

Dr. Angel has effectively established discovery, research, and development teams and projects, bringing several pharmaceutical drugs to market. As an excellent communicator and negotiator, Dr. Angel has led international projects and worked closely with high-profile regulatory, government, and industry leaders.

Dr. Angel is the author of over 100 book chapters, papers, abstracts, and patents. Outside of his professional work, he is a passionate painter, music lover, and avid traveler who speaks several languages.

Michelle Yanez has been our Chief Financial Officer since April 2023, prior to which she served as our Corporate Controller since May 2022. Ms. Yanez is a senior financial executive with over 25 years of experience in public and privately held biotech, pharmaceutical, and life science companies. Ms. Yanez’ experience includes a broad range of responsibilities in a highly complex and regulated market. She also brings deep corporate governance experience through her work with corporate boards, including audit and finance committees.

Since June 2024, Ms. Yanez also serves as Chief Financial Officer for Telomir Pharmaceuticals (Nasdaq: TELO), a pre-clinical-stage pharmaceutical company, seeking to lead development in age-reversal science, by focusing on the development of a novel small molecule designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. From May 2002 until its acquisition in April 2022, Ms. Yanez held various leadership positions at BioDelivery Sciences International, Inc. (Nasdaq: BDSI). In her role, she led financial offerings, managed due diligence for product acquisitions and financings and managed finance documents and filings for the tender offer, leading to the acquisition of BioDelivery Sciences in April 2022.

Ms. Yanez also serves as a non-employee director of Inhibitor Therapeutics, Inc. (OTCQB: INTI), a publicly traded pharmaceutical development company focused on therapeutics for certain cancers and non-cancerous proliferation disorders, since December 2022. Ms. Yanez is also Co-Founder and Chief Financial Officer of Santander Pharma Consulting, a privately held life sciences consulting firm that provides business development and commercial strategy services to pharmaceutical, medical device, and life science companies offering guidance throughout all stages of commercial development, from inception to product launch, since February 2024.

Ms. Yanez earned her B.A. in Business Management from University South Florida and further distinguished her acumen with an MBA in Strategic Leadership from Rutgers School of Business, Cum Laude.